



Toviaz® (fesoterodine fumarate) – New indication

- On June 17, 2021, the [FDA approved](#) Pfizer's [Toviaz \(fesoterodine fumarate\)](#), for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg.
- Toviaz is also approved for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.
- The approval of Toviaz for the new indication was based on a randomized, open-label study consisting of a 12-week efficacy phase followed by a 12-week safety extension phase in pediatric patients from 6 years to 17 years of age. During the 12-week efficacy phase, 124 patients were randomized to receive Toviaz 4 mg, Toviaz 8 mg, or active comparator orally once daily. The primary efficacy endpoint was the mean change from baseline in maximum cystometric bladder capacity (MCBC) at week 12.
 - Treatment with Toviaz 4 mg or 8 mg daily resulted in improvements from baseline to week 12 in the primary efficacy endpoint, MCBC, for pediatric patients, with numerically higher changes from baseline for Toviaz 8 mg daily than for Toviaz 4 mg daily. The change from baseline with Toviaz 4 mg was 58.1 (95% CI: 28.8, 87.4) and with Toviaz 8 mg the change from baseline was 83.4 (95% CI: 54.2, 112.5).
- The most common adverse reactions ($\geq 2\%$) with Toviaz use in pediatric patients with NDO were diarrhea, urinary tract infection, dry mouth, constipation, abdominal pain, nausea, increased weight, and headache.
- In pediatric patients weighing greater than 25 kg and up to 35 kg, the recommended dose of Toviaz is 4 mg orally once daily. If needed, dosage may be increased to Toviaz 8 mg orally once daily.
- In pediatric patients weighing greater than 35 kg, the recommended starting dosage of Toviaz is 4 mg orally once daily. After one week, the dose should be increased to 8 mg orally once daily.
- Refer to the Toviaz drug label for dosing for OAB.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.